

Colin D. Chapman

PARTNER

San Francisco

P +1 650 463 5490

Silicon Valley

P +1 650 321 2400

Colin is co-head of the Strategic Transactions & Licensing group.

Colin is a partner in our Silicon Valley office, specializing in the areas of corporate partnering and strategic alliances, technology protection, and licensing and commercialization of intellectual property and technology assets. Colin's focus is representing emerging growth companies both in the United States and abroad. Additionally, Colin has considerable experience representing venture capitalists and multinational companies requiring such expertise.

Colin represents his clients in negotiating strategic alliances and/or licensing and commercial arrangements with companies such as Amazon, Apple, BMW, Bristol Myers Squibb, Cardinal Health, Chevron Corporation, Cisco, Disney, Exxon-Mobile, Ford, Intel, JP Morgan Chase, Kaiser, Pfizer, Roche, Salesforce.com, Tesla, Thermo Fisher Scientific and Visa. He has also negotiated commercial and clinical arrangements with many major research institutions.

Colin has spoken in a number of forums and authored articles and books on intellectual property matters and related business strategies that affect strategic alliances. He is an author of the treatise, "Corporate Partnering, Structuring and Negotiating Domestic and International Strategic Alliance" (Aspen Publishers), and a Chapter author of both "The Acquisition and Sale of the Emerging Growth Company: The M&A Exit" (Glasser Legal Works) and "Venture Capital and Public Offering Negotiation" (Aspen Publishers). He is also an invited speaker at numerous conferences including with the Practicing Law Institute, the Biotechnology Law Institute, the Technology Transfer Conference, and Executive Programs at the Stanford Graduate School of Business.

Credentials

EDUCATION

- · University of Michigan Law School, J.D.
- University of California, Berkeley, B.A., History and Political Science

BAR ADMISSIONS

California

Focus Areas

Strategic Transactions & Licensing
Data Privacy
Mergers & Acquisitions
Fund Investments in Companies
Life Sciences Licensing & Strategic Partnering
Seed, Venture and Growth Financings
Life Sciences

Related News & Insights

CLIENT NEWS

Ripple Announces Agreement to Acquire Hidden Road for \$1.25B

Gunderson Dettmer Client Cyral Acquired by Varonis Systems

CLIENT NEWS

Twelve Announces \$645M Financing to De-Fossilize Manufacturing Processes

CLIENT NEWS

Gunderson Dettmer Represented Skuad in \$61M Acquisition by Payoneer

CLIENT NEWS

Monarch Tractor Announces \$133M Series C Financing

CLIENT NEWS

Incode Announces Acquisition of MetaMap

CLIENT NEWS

Corelight Announces \$150M Series E Financing Led by Accel

CLIENT NEWS

Chile-based Ceibo Announces \$30M Series B

CLIENT NEWS

Miroculus Acquired by INTEGRA Biosciences

CLIENT NEWS

BillionToOne Announces \$48.5M Equity and \$35M Debt Financing for Next-Gen Molecular Diagnostics

CLIENT NEWS

Customer Notification Platform OneSignal Announces \$50M Series C Financing

CLIENT NEWS

Ancora Biotech Announces \$60M Series A Co-Led by Lightspeed Venture Partners and SR One

CLIENT NEWS

Punnet Acquisition by Perforce

I apper requisition by I choice